Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
BUSINESS

Govt Approves Rs 22,325 Crore Sops Plan for Pharma


The Union Cabinet on Wednesday extended the production-linked incentive (PLI) scheme for the pharmaceutical and technology hardware sectors, approving Rs 15,000 crore and Rs 7,325 crore worth of incentives, respectively, to encourage domestic manufacturing. The cabinet, chaired by Prime Minister Narendra Modi, said the PLI scheme for pharma will be effective over FY21-FY29, while manufacturers of laptops, tablets, all-in-one personal computers and servers, will enjoy the benefits for a four-year period. The move will boost local manufacturing and reduce India’s dependence on imports. The government estimates the scheme will help the pharma sector clock incremental sales of Rs 2.94 trillion and incremental exports worth Rs 1.96 trillion during the six years, while the IT hardware segment will be able to build production capacity worth Rs 3.26 trillion, of which 75 per cent, or Rs 2.45 trillion, will be for exports, in the next four years. The government also expects the top five global manufacturers of laptops and tablets, including Apple, Dell and HP, to set up local units. The PLI scheme for pharmaceuticals, the government said, is expected to generate employment for both skilled and un-skilled personnel, estimated at 20,000 direct and 80,000 indirect jobs.
“The objective of the scheme is to enhance India’s manufacturing capabilities by increasing investments and production in the sector, and contributing to product diversification to high-value goods in the pharmaceutical sector,” electronics and information technology minister Ravi Shankar Prasad said. It is expected to promote innovation for the development of complex and high-tech products, including emerging therapies and in-vitro diagnostic devices, besides building self-reliance in key drugs. It is also expected to improve accessibility and affordability of medical products, including orphan drugs, for the Indian population, it added.
The manufacturers of pharmaceutical goods registered in India will be segregated based on their global manufacturing revenue (GMR) to ensure wider applicability of the scheme across the industry and to meet the objectives of the scheme.

Get Daily Prediction & Stocks Tips On Your Mobile